
ESTA Stock Forecast & Price Target
ESTA Analyst Ratings
Bulls say
Establishment Labs Hldgs is a leader in the medical technology industry, with strong Q2 revenue and a successful product line, including the innovative breast implant product, Motiva. With a growing list of distributors and accounts globally, and an expanding product line, the company is expected to see long-term growth and strong revenue contribution. Combined with a successful cash flow outlook and a low complication rate for their tissue-preserving procedure, Establishment Labs Holdings Inc is a strong buy for investors.
Bears say
Establishment Labs Hldgs is expected to face significant challenges in the near future due to inventory reserves, increased operating expenses, and potential funding needs. While the company has a strong cash balance and plans to reach free cash flow positivity by 2026, the risks of an economic recession, competition, and unsuccessful launch of pipeline products could hinder its progress. However, the company's innovative R&D and attractive gross margin may warrant a higher valuation in the MedTech sector.
This aggregate rating is based on analysts' research of Establishment Labs Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ESTA Analyst Forecast & Price Prediction
Start investing in ESTA
Order type
Buy in
Order amount
Est. shares
0 shares